- United Kingdom
- /
- Biotech
- /
- LSE:GNS
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
Genus plc (LON:GNS) will pay a dividend of £0.217 on the 6th of December. This payment means the dividend yield will be 1.6%, which is below the average for the industry.
Check out our latest analysis for Genus
Genus' Projected Earnings Seem Likely To Cover Future Distributions
If it is predictable over a long period, even low dividend yields can be attractive. Prior to this announcement, the company was paying out 266% of what it was earning. This situation certainly isn't ideal, and could place significant strain on the balance sheet if it continues.
According to analysts, EPS should be several times higher next year. If the dividend continues along recent trends, we estimate the payout ratio will be 39%, which would make us comfortable with the dividend's sustainability, despite the levels currently being elevated.
Genus Has A Solid Track Record
The company has a sustained record of paying dividends with very little fluctuation. The dividend has gone from an annual total of £0.177 in 2014 to the most recent total annual payment of £0.32. This works out to be a compound annual growth rate (CAGR) of approximately 6.1% a year over that time. The dividend has been growing very nicely for a number of years, and has given its shareholders some nice income in their portfolios.
Dividend Growth May Be Hard To Achieve
Investors could be attracted to the stock based on the quality of its payment history. However, initial appearances might be deceiving. Unfortunately, Genus' earnings per share has been essentially flat over the past five years, which means the dividend may not be increased each year.
Genus' Dividend Doesn't Look Sustainable
In summary, while it's good to see that the dividend hasn't been cut, we are a bit cautious about Genus' payments, as there could be some issues with sustaining them into the future. Although they have been consistent in the past, we think the payments are a little high to be sustained. We would probably look elsewhere for an income investment.
Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. For example, we've picked out 2 warning signs for Genus that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:GNS
Genus
Produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.
Adequate balance sheet with moderate growth potential.
Market Insights
Weekly Picks

The Future of Social Sharing Is Private and People Are Ready

EU#3 - From Philips Management Buyout to Europe’s Biggest Company
Booking Holdings: Why Ground-Level Travel Trends Still Favor the Platform Giants

A fully integrated LNG business seems to be ignored by the market.
Recently Updated Narratives

Sunny Returns with On the Beach
High Quality Business and a true compounding machine

Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
Popular Narratives
Undervalued Key Player in Magnets/Rare Earth

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

AMZN: Acceleration In Cloud And AI Will Drive Margin Expansion Ahead
Trending Discussion
